source
- Axiom's stem cell therapy shows zero mortality in phase-1 trial for newborn brain injuriesAxiom Biosciences reported that its mesenchymal stem cell (MSC) therapy achieved a 0% mortality rate over two years in a phase‑1 study of newborns with severe brain injuries. The nine‑patient trial…
- I&I startup Attovia Therapeutics files for IPO as biotech listing wave gains paceAttovia Therapeutics, an I&I startup that develops biologics, filed a registration statement to go public on Tuesday after the market closed. The filing brings the number of biotech companies expe…